Phase 3 Double-Blind, Active Controlled, 3-Stage Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma.
Fairfax Office
Gainesville Office
Arlington Office
Alexandria Office
“A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)”
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)